Pluri Inc. (PLUR)

NASDAQ: PLUR · IEX Real-Time Price · USD
1.04
+0.01 (0.97%)
Aug 16, 2022 2:38 PM EDT - Market open
0.97%
Market Cap 33.64M
Revenue (ttm) 234,000
Net Income (ttm) -46.81M
Shares Out 32.35M
EPS (ttm) -1.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 51,393
Open 1.04
Previous Close 1.03
Day's Range 1.00 - 1.06
52-Week Range 0.94 - 3.22
Beta 1.78
Analysts Buy
Price Target n/a
Earnings Date Sep 12, 2022

About PLUR

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of ... [Read more...]

Industry Biotechnology
Founded 2001
CEO Yaky Yanay
Employees 153
Stock Exchange NASDAQ
Ticker Symbol PLUR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
n/a
Analyst Consensus: Buy
Stock Forecasts

News

Pluri CEO Issues Shareholder Update

HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, toda...

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company's Strategy to Leverage its Innova...

HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, today announced its name change (from Pluristem Thera...

Pluristem (PSTI) Phase III Study Misses Goal, Stock Down

Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.

Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery

Pluristem Therapeutics Inc (NASDAQ: PSTI) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fr...

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluri...

Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership

Closing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET  at Nasdaq MarketSite in Times Square, New York

Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in B...

HAIFA, Israel, March 23, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company developing novel cell therapies, today announced positive final...

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company (“Pluristem”), and Tnuva Group (“Tnuva Group” or “Tnuva”), Isra...

Pluristem CEO Issues Shareholder Update

HAIFA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Exec...

Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform

HAIFA, Israel, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI) (“Pluristem”) and Israel's largest food producer Tnuva Group (“Tnuv...

Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform

Pluristem Therapeutics Inc (NASDAQ: PSTI) and Tnuva Group have collaborated to develop, manufacture and commercialize cultured cell-based products for the food industry.  Tnuva Group is the largest food...

Biotechnology Company Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish...

HAIFA, Israel, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI) (“Pluristem” or “the Company”), a leading biotechnology company, and Tnuva Group (“Tnuva Group" o...

Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS

Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.

Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with CO...

HAIFA, Israel, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced topline results from its Phase II...

Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Sur...

Having recruited patients in the U.S., Europe and Israel, t he Company anticipates topline results in the third calendar quarter of 2022

Pluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX ...

Following achievements met in the project, the IIA to provide an additional budget to advance work of CRISPR-IL National Consortium, in which Pluristem is leading the Pharma group, and working with othe...

Pluristem Appoints Prof. Varda Shalev MD and Mr.

HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Var...

Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout

HAIFA, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company announced today that it is bringing its Acute Resp...

Pluristem Stock is Trading Higher After €20M Non-Dilutive Funding from European Investment Bank

Pluristem Therapeutics Inc (NASDAQ: PSTI) has received €20 million (approximately $24 million) from the European Investment Bank (EIB), the first disbursement of three tranches of funding. The disbursem...

Pluristem Stock Is Trading Higher As PLX-R18 Shows Regenerative Potential In Patients After Bone Marrow Transplant

Pluristem Therapeutics Inc (NASDAQ: PSTI) has reported positive topline results from Phase 1 study evaluating intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery follo...

Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering

HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic prod...

Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem's ARDS Associated With CO...

HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic prod...

Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study

HAIFA, Israel, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic pr...

Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 Demonstrating Safety and Efficacy at the...

HAIFA, Israel, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic pr...

World Experts in Infectious Diseases & Critical Care Form Pluristem's COVID-19 Steering Committee

HAIFA, Israel, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, toda...